El tratamiento con quimioterapia hoy en pacientes HER2 negativo: el papel de la eribulina - page 38

Study Design
A single-arm, open-label, multicentre, Phase Ib/II study of eribulin plus
pembrolizumab as first-, second- and third-line therapy in patients with
triple-negative metastatic breast cancer